180 related articles for article (PubMed ID: 37368466)
1. Mass Spectrometry and Pharmacological Approaches to Measuring Cooption and Reciprocal Activation of Receptor Tyrosine Kinases.
Linzer J; Phelps Z; Vummidi S; Lee BYE; Coant N; Haley JD
Proteomes; 2023 Jun; 11(2):. PubMed ID: 37368466
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response.
Szerlip NJ; Pedraza A; Chakravarty D; Azim M; McGuire J; Fang Y; Ozawa T; Holland EC; Huse JT; Jhanwar S; Leversha MA; Mikkelsen T; Brennan CW
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3041-6. PubMed ID: 22323597
[TBL] [Abstract][Full Text] [Related]
3. Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy.
Brevet M; Shimizu S; Bott MJ; Shukla N; Zhou Q; Olshen AB; Rusch V; Ladanyi M
J Thorac Oncol; 2011 May; 6(5):864-74. PubMed ID: 21774103
[TBL] [Abstract][Full Text] [Related]
4. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.
Pillay V; Allaf L; Wilding AL; Donoghue JF; Court NW; Greenall SA; Scott AM; Johns TG
Neoplasia; 2009 May; 11(5):448-58, 2 p following 458. PubMed ID: 19412429
[TBL] [Abstract][Full Text] [Related]
5. Targeting receptor tyrosine kinases for chemoprevention by green tea catechin, EGCG.
Shimizu M; Shirakami Y; Moriwaki H
Int J Mol Sci; 2008 Jun; 9(6):1034-1049. PubMed ID: 19325845
[TBL] [Abstract][Full Text] [Related]
6. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A
Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329
[TBL] [Abstract][Full Text] [Related]
7. Receptor tyrosine kinases fall into distinct classes based on their inferred signaling networks.
Wagner JP; Wolf-Yadlin A; Sevecka M; Grenier JK; Root DE; Lauffenburger DA; MacBeath G
Sci Signal; 2013 Jul; 6(284):ra58. PubMed ID: 23861540
[TBL] [Abstract][Full Text] [Related]
8. SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer.
Matalkah F; Martin E; Zhao H; Agazie YM
Breast Cancer Res; 2016 Jan; 18(1):2. PubMed ID: 26728598
[TBL] [Abstract][Full Text] [Related]
9. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
Thomson S; Petti F; Sujka-Kwok I; Epstein D; Haley JD
Clin Exp Metastasis; 2008; 25(8):843-54. PubMed ID: 18696232
[TBL] [Abstract][Full Text] [Related]
10. Broad-spectrum receptor tyrosine kinase inhibitors overcome
Graves-Deal R; Bogatcheva G; Rehman S; Lu Y; Higginbotham JN; Singh B
Oncotarget; 2019 Feb; 10(13):1320-1333. PubMed ID: 30863492
[TBL] [Abstract][Full Text] [Related]
11. Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma.
Ou WB; Hubert C; Corson JM; Bueno R; Flynn DL; Sugarbaker DJ; Fletcher JA
Neoplasia; 2011 Jan; 13(1):12-22. PubMed ID: 21245936
[TBL] [Abstract][Full Text] [Related]
12. Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer.
Hu S; Dai H; Li T; Tang Y; Fu W; Yuan Q; Wang F; Lv G; Lv Y; Fan X; Zhang S; Jin R; Shen Y; Lin F; Ye X; Ding M; Yang Y; Lei C
Cancer Lett; 2016 Nov; 382(1):32-43. PubMed ID: 27569653
[TBL] [Abstract][Full Text] [Related]
13. Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatase-1B.
Haj FG; Markova B; Klaman LD; Bohmer FD; Neel BG
J Biol Chem; 2003 Jan; 278(2):739-44. PubMed ID: 12424235
[TBL] [Abstract][Full Text] [Related]
14. The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells.
Meyer AS; Miller MA; Gertler FB; Lauffenburger DA
Sci Signal; 2013 Aug; 6(287):ra66. PubMed ID: 23921085
[TBL] [Abstract][Full Text] [Related]
15. Direct modulation of the protein kinase A catalytic subunit α by growth factor receptor tyrosine kinases.
Caldwell GB; Howe AK; Nickl CK; Dostmann WR; Ballif BA; Deming PB
J Cell Biochem; 2012 Jan; 113(1):39-48. PubMed ID: 21866565
[TBL] [Abstract][Full Text] [Related]
16. The role of platelet-derived growth factor receptor in eotaxin signaling of eosinophils.
Adachi T; Hanaka S; Yano T; Yamamura K; Yoshihara H; Nagase H; Chihara J; Ohta K
Int Arch Allergy Immunol; 2006; 140 Suppl 1():28-34. PubMed ID: 16772724
[TBL] [Abstract][Full Text] [Related]
17. Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib.
Kim S; Kim TM; Kim DW; Kim S; Kim M; Ahn YO; Keam B; Heo DS
Cancer Res Treat; 2019 Jul; 51(3):951-962. PubMed ID: 30309221
[TBL] [Abstract][Full Text] [Related]
18. Receptor Tyrosine Kinases: Principles and Functions in Glioma Invasion.
Nakada M; Kita D; Teng L; Pyko IV; Watanabe T; Hayashi Y; Hamada JI
Adv Exp Med Biol; 2020; 1202():151-178. PubMed ID: 32034713
[TBL] [Abstract][Full Text] [Related]
19. Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells.
Mueller KL; Hunter LA; Ethier SP; Boerner JL
Cancer Res; 2008 May; 68(9):3314-22. PubMed ID: 18451158
[TBL] [Abstract][Full Text] [Related]
20. Genotype-determined EGFR-RTK heterodimerization and its effects on drug resistance in lung Cancer treatment revealed by molecular dynamics simulations.
Zhu M; Wang DD; Yan H
BMC Mol Cell Biol; 2021 Jun; 22(1):34. PubMed ID: 34112110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
